LEADER 03531nam 2200877z- 450 001 9910566462403321 005 20220506 035 $a(CKB)5680000000037757 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81161 035 $a(oapen)doab81161 035 $a(EXLCZ)995680000000037757 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aApplication of Novel Methods for Mycotoxins Analysis 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (108 p.) 311 08$a3-0365-3523-3 311 08$a3-0365-3524-1 330 $aCrop contamination by mycotoxins is a global problem that poses significant economic burdens due to a number of factors, including the food/feed losses that are caused by reduced production rates; the resulting adverse effects on human and animal health and productivity; and the trade losses associated with the costs incurred by inspection, sampling, and analysis before and after shipments. In this scenario, the development of fit-for-purpose analytical methods for regulated and (re)-emerging mycotoxins continues to be a dynamic research area. Some of the current trends in this research area are presented in this book. The collected contributions address either the need for improved methods for mycotoxin detection addressed by new or incoming regulation (ergot alkaloids and Alternaria toxins) as well as methods for the detection of multiple mycotoxins. New approaches to enhance the performance of well-established methodologies, such as the enzyme-linked immunosorbent assay (ELISA) and fluorescence polarization immunoassays (FPIA), are also addressed. 606 $aAnalytical chemistry$2bicssc 606 $aChemistry$2bicssc 606 $aResearch & information: general$2bicssc 610 $aaflatoxin B1 610 $aalternariol 610 $aantibody 610 $acereal products 610 $acollaborative study 610 $adairy feed 610 $adetection methods 610 $aELISA 610 $aergot alkaloids 610 $aesterification 610 $afood safety 610 $aFPIA 610 $aFusarium toxins 610 $ahapten design 610 $aHPLC 610 $ahydrazinolysis 610 $aI-ELISA 610 $aimmunoassay 610 $aLC-MS/MS method 610 $alinker site 610 $aliquid chromatography-mass spectrometry 610 $amilk powder 610 $amonoclonal antibody (mAb) 610 $amycotoxin 610 $an/a 610 $aoccurrence 610 $aofficial control 610 $aOTA 610 $apeanut 610 $arecombinant AflR gene 610 $asum parameter method 610 $aswine feed 610 $atracer 610 $atrichothecenes 610 $aUHPLC-MS/MS 610 $aVICAM 610 $awheat 610 $awheat flour 610 $azearalenone 615 7$aAnalytical chemistry 615 7$aChemistry 615 7$aResearch & information: general 700 $aCiasca$b Biancamaria$4edt$01280990 702 $aLattanzio$b Veronica Maria Teresa$4edt 702 $aCiasca$b Biancamaria$4oth 702 $aLattanzio$b Veronica Maria Teresa$4oth 906 $aBOOK 912 $a9910566462403321 996 $aApplication of Novel Methods for Mycotoxins Analysis$93017801 997 $aUNINA LEADER 03966nam 2201093z- 450 001 9910576881803321 005 20220621 035 $a(CKB)5720000000008357 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84467 035 $a(oapen)doab84467 035 $a(EXLCZ)995720000000008357 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDiagnosis and Management of Heart Failure 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (202 p.) 311 08$a3-0365-4154-3 311 08$a3-0365-4153-5 330 $aHeart failure prevalence continues to rise globally. Regardless of the underlying etiology, heart failure remains a progressive disease, largely irreversible and end-stage heart failure requires transplantation. Book focuses on the challenges and recent advances of diagnosis, treatment and prevention of heart failure with or without associated comorbidities. We hope that readers will appreciate the wide breadth of topics and clinical utility of the articles and reviews included to this book collection. 606 $aCardiovascular medicine$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $a24-h ECG monitoring 610 $a2D echocardiography 610 $aacute myocardial infarction 610 $aadverse left ventricular remodeling 610 $aangiotensin receptor-neprilysin inhibitor 610 $aarteriovenous fistulas 610 $abiomarkers 610 $ablood biomarkers 610 $acardiac allograft vasculopathy 610 $acardiopulmonary exercise test 610 $acardiovascular disease 610 $achronic heart failure 610 $achronic kidney disease 610 $aclinical assessment 610 $acongestion 610 $adiagnosis 610 $adilated cardiomyopathy 610 $aE/e' ratio 610 $aechocardiography 610 $aedema 610 $aejection fraction 610 $aendothelial dysfunction 610 $aepicardial fat 610 $afatty liver 610 $afibrosis 610 $afluid management 610 $agalectin-3 610 $aheart failure 610 $aheart failure readmission 610 $aheart rate variability 610 $aheart transplant 610 $aheart transplant rejection 610 $aHFrEF 610 $ahospitalization predictor 610 $aleft atrial strain 610 $aleft ventricle end-diastolic diameter 610 $aleft ventricle outflow tract velocity-time integral 610 $aleft ventricular-arterial coupling 610 $alongitudinal strain 610 $amatrix metalloproteinases 610 $amortality 610 $amyocardial infarction 610 $an/a 610 $aNT-proBNP 610 $aoverhydration 610 $apacing parameters 610 $apreserved ejection fraction 610 $apreserved left ventricular ejection fraction 610 $apulmonary hypertension 610 $areduced left ventricular ejection fraction 610 $arisk stratification 610 $asensing parameters 610 $ashort-term prognosis 610 $asoluble ST2 610 $aST-segment elevation myocardial infarction 610 $atissue inhibitors of metalloproteinases 610 $atransthoracic echocardiography 610 $atype 2 diabetes mellitus 610 $aventilatory inefficiency 615 7$aCardiovascular medicine 615 7$aMedicine and Nursing 700 $aGladysheva$b Inna P$4edt$01300064 702 $aSullivan$b Ryan D$4edt 702 $aGladysheva$b Inna P$4oth 702 $aSullivan$b Ryan D$4oth 906 $aBOOK 912 $a9910576881803321 996 $aDiagnosis and Management of Heart Failure$93025392 997 $aUNINA